Total Payments
$569,574
2024 Payments
$69,014
Companies
18
Transactions
402
Medicare Patients
378
Medicare Billing
$47,358
Payment Breakdown by Category
Consulting$376,394 (66.1%)
Travel$118,597 (20.8%)
Other$58,424 (10.3%)
Research$9,159 (1.6%)
Food & Beverage$6,944 (1.2%)
Education$56.25 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $376,394 | 99 | 66.1% |
| Travel and Lodging | $118,597 | 168 | 20.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $47,926 | 29 | 8.4% |
| Unspecified | $9,159 | 18 | 1.6% |
| Honoraria | $9,010 | 2 | 1.6% |
| Food and Beverage | $6,944 | 83 | 1.2% |
| Compensation for serving as faculty or as a speaker for a medical education program | $1,488 | 2 | 0.3% |
| Education | $56.25 | 1 | 0.0% |
Payments by Type
General
$560,415
384 transactions
Research
$9,159
18 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk AS | $278,326 | 104 | $0 (2024) |
| Novo Nordisk Inc | $79,413 | 53 | $0 (2024) |
| Eli Lilly and Company | $68,472 | 95 | $0 (2024) |
| Boehringer Ingelheim International GmbH | $24,193 | 7 | $0 (2022) |
| Corcept Therapeutics | $23,072 | 26 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $17,185 | 22 | $0 (2024) |
| Mannkind Corporation | $14,361 | 19 | $0 (2020) |
| CeQur Corporation | $14,129 | 3 | $0 (2023) |
| VERTEX PHARMACEUTICALS INCORPORATED | $10,438 | 25 | $0 (2024) |
| AstraZeneca UK Limited | $8,519 | 7 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $69,014 | 73 | AstraZeneca Pharmaceuticals LP ($15,857) |
| 2023 | $43,227 | 69 | Corcept Therapeutics ($12,975) |
| 2022 | $59,107 | 41 | Novo Nordisk AS ($16,010) |
| 2021 | $54,625 | 18 | Novo Nordisk AS ($34,875) |
| 2020 | $49,736 | 35 | Novo Nordisk AS ($29,132) |
| 2019 | $101,995 | 52 | Novo Nordisk AS ($49,360) |
| 2018 | $147,133 | 72 | Novo Nordisk AS ($90,267) |
| 2017 | $44,736 | 42 | Novo Nordisk AS ($38,824) |
All Payment Transactions
402 individual payment records from CMS Open Payments — Page 1 of 17
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Corcept Therapeutics | Korlym (Drug) | Travel and Lodging | Cash or cash equivalent | $336.75 | General |
| Category: Endocrinology | ||||||
| 12/11/2024 | VERTEX PHARMACEUTICALS INCORPORATED | — | Consulting Fee | Cash or cash equivalent | $4,000.00 | General |
| 12/11/2024 | VERTEX PHARMACEUTICALS INCORPORATED | — | Travel and Lodging | In-kind items and services | $32.16 | General |
| 12/11/2024 | VERTEX PHARMACEUTICALS INCORPORATED | — | Travel and Lodging | In-kind items and services | $26.25 | General |
| 12/11/2024 | VERTEX PHARMACEUTICALS INCORPORATED | — | Travel and Lodging | In-kind items and services | $23.50 | General |
| 11/21/2024 | Corcept Therapeutics | Korlym (Drug) | Travel and Lodging | In-kind items and services | $286.95 | General |
| Category: Endocrinology | ||||||
| 11/21/2024 | Corcept Therapeutics | Korlym (Drug) | Travel and Lodging | In-kind items and services | $206.05 | General |
| Category: Endocrinology | ||||||
| 11/21/2024 | Corcept Therapeutics | Korlym (Drug) | Travel and Lodging | In-kind items and services | $171.42 | General |
| Category: Endocrinology | ||||||
| 11/21/2024 | Corcept Therapeutics | Korlym (Drug) | Travel and Lodging | In-kind items and services | $102.20 | General |
| Category: Endocrinology | ||||||
| 11/21/2024 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $29.00 | General |
| Category: Endocrinology | ||||||
| 11/21/2024 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $22.00 | General |
| Category: Endocrinology | ||||||
| 11/15/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $1,074.00 | General |
| 11/15/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| 11/15/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| 11/15/2024 | VERTEX PHARMACEUTICALS INCORPORATED | — | Travel and Lodging | In-kind items and services | $345.88 | General |
| 11/15/2024 | VERTEX PHARMACEUTICALS INCORPORATED | — | Travel and Lodging | In-kind items and services | $301.61 | General |
| 11/15/2024 | VERTEX PHARMACEUTICALS INCORPORATED | — | Travel and Lodging | In-kind items and services | $211.11 | General |
| 11/15/2024 | VERTEX PHARMACEUTICALS INCORPORATED | — | Food and Beverage | In-kind items and services | $38.50 | General |
| 11/15/2024 | VERTEX PHARMACEUTICALS INCORPORATED | — | Food and Beverage | In-kind items and services | $24.00 | General |
| 11/15/2024 | VERTEX PHARMACEUTICALS INCORPORATED | — | Food and Beverage | In-kind items and services | $23.00 | General |
| 11/15/2024 | VERTEX PHARMACEUTICALS INCORPORATED | — | Food and Beverage | In-kind items and services | $18.50 | General |
| 11/13/2024 | Corcept Therapeutics | Korlym (Drug) | Consulting Fee | Cash or cash equivalent | $4,000.00 | General |
| Category: Endocrinology | ||||||
| 11/06/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $537.00 | General |
| 10/17/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $5,370.00 | General |
| 10/15/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $500.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| NN9924-4558 | Novo Nordisk AS | $2,750 | 1 |
| CATALYST | Corcept Therapeutics | $1,771 | 7 |
| A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of LX4211 as Adjunct Therapy in Adult Patients With Type 1 | SANOFI-AVENTIS U.S. LLC | $1,739 | 5 |
| Patient exit interview manuscript: Insights into the Patient Experience with Type 1 Diabetes: Exit Interviews from Phase 3 Studies of Sotagliflozin | SANOFI-AVENTIS U.S. LLC | $1,308 | 1 |
| PRO-DTSQ: Improved treatment satisfaction in patients with type 1 diabetes treated with sotagliflozin plus insulin vs insulin alone | SANOFI-AVENTIS U.S. LLC | $1,149 | 1 |
| Patients with Type 1 Diabetes Value Increased Glucose Stability and Associate it with Improved Well-being: Exit Interviews from Sotagliflozin Phase 3 Study | SANOFI-AVENTIS U.S. LLC | $443.18 | 3 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 92 | 227 | $51,765 | $12,164 |
| 2022 | 2 | 94 | 248 | $55,683 | $14,131 |
| 2021 | 2 | 98 | 220 | $49,662 | $12,419 |
| 2020 | 3 | 94 | 174 | $37,413 | $8,643 |
Total Patients
378
Total Services
869
Medicare Billing
$47,358
Procedure Codes
9
All Medicare Procedures & Services
9 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 62 | 151 | $42,031 | $10,235 | 24.4% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2023 | 30 | 76 | $9,734 | $1,929 | 19.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 61 | 159 | $44,202 | $11,771 | 26.6% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2022 | 33 | 89 | $11,481 | $2,360 | 20.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 67 | 150 | $40,632 | $10,519 | 25.9% |
| 95251 | Ambulatory continuous glucose (sugar) including interpretation and report for a minimum of 72 hours | Office | 2021 | 31 | 70 | $9,030 | $1,900 | 21.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 57 | 108 | $28,131 | $6,129 | 21.8% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 20 | 23 | $3,823 | $1,387 | 36.3% |
| 95251 | Ambulatory continuous glucose (sugar) including interpretation and report for a minimum of 72 hours | Office | 2020 | 17 | 43 | $5,459 | $1,127 | 20.6% |
About Dr. John Buse, MD
Dr. John Buse, MD is a Endocrinology, Diabetes & Metabolism healthcare provider based in Chapel Hill, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/13/2006. The National Provider Identifier (NPI) number assigned to this provider is 1336164680.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Buse, MD has received a total of $569,574 in payments from pharmaceutical and medical device companies, with $69,014 received in 2024. These payments were reported across 402 transactions from 18 companies. The most common payment nature is "Consulting Fee" ($376,394).
As a Medicare-enrolled provider, Buse has provided services to 378 Medicare beneficiaries, totaling 869 services with total Medicare billing of $47,358. Data is available for 4 years (2020–2023), covering 9 distinct procedure/service records.
Ad
Practice Information
- Specialty Endocrinology, Diabetes & Metabolism
- Other Specialties Diabetes & Metabolism
- Location Chapel Hill, NC
- Active Since 07/13/2006
- Last Updated 07/08/2007
- Taxonomy Code 207RE0101X
- Entity Type Individual
- NPI Number 1336164680
Products in Payments
- Victoza (Drug) $77,425
- JARDIANCE (Drug) $24,193
- Korlym (Drug) $23,072
- Rybelsus (Drug) $14,760
- AFREZZA (Drug) $14,361
- CeQur Simplicity (Device) $14,129
- Ozempic (Drug) $13,505
- TRULICITY (Drug) $12,942
- Xultophy 100/3.6 (Drug) $8,206
- Saxenda (Drug) $7,995
- Dasiglucagon (Device) $3,750
- SAR439954 (Drug) $3,647
- DEXCOM G6 CGM SYSTEM (Device) $3,549
- SOTAGLIFLOZIN (Drug) $2,437
- XARELTO (Drug) $2,000
- Dexcom G6 Transmitter (Medical Supply) $892.50
- Tresiba (Drug) $500.00
- MOUNJARO (Drug) $456.46
- FARXIGA (Drug) $278.88
- TOUJEO (Drug) $149.91
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Endocrinology, Diabetes & Metabolism Doctors in Chapel Hill
Dr. Atil Kargi, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $74,990
Endocrinology, Diabetes & Metabolism $74,990
Sadia Ejaz, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $14,296
Endocrinology, Diabetes & Metabolism $14,296
Dr. Rebecca Vitale, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $5,000
Endocrinology, Diabetes & Metabolism $5,000
Dr. Janet Rubin, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $3,818
Endocrinology, Diabetes & Metabolism $3,818
Karla Pou, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $478.70
Endocrinology, Diabetes & Metabolism $478.70
Tahereh Ghorbani Rodriguez, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $432.76
Endocrinology, Diabetes & Metabolism $432.76